Results 91 to 100 of about 38,942 (318)

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB

Retina, 2017
Purpose: To evaluate the systemic pharmacokinetics (PKs) of aflibercept, bevacizumab, and ranibizumab in patients with neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal vein occlusion (RVO). Methods: Prospective,
R. Avery, A. Castellarin, N. Steinle, D. Dhoot, D. Pieramici, R. See, Steven C. Couvillion, M. Nasir, M. Rabena, M. Maia, Sherri A Van Everen, K. Le, W. Hanley   +12 more
semanticscholar   +1 more source

Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration

JAMA ophthalmology, 2020
Key Points Question Does SB11, a proposed ranibizumab biosimilar product, have equivalent best-corrected visual acuity (BCVA) and optical coherence tomography central subfield thickness (CST) outcomes and a similar safety profile to the reference ...
S. Woo, M. Veith, J. Hamouz, J. Ernest, D. Zalewski, J. Studnicka, A. Vajas, A. Papp, Vogt Gabor, J. Luu, V. Matušková, Y. Yoon, T. Pregun, Taehyung Kim, Donghoon Shin, N. Bressler   +15 more
semanticscholar   +1 more source

Intravitreal anti‐vascular endothelial growth factor injections and risks of stroke in patients with neovascular age‐related macular degeneration—A registry‐based cohort study

Acta Ophthalmologica, EarlyView.
Abstract Background Intravitreal Anti‐Vascular Endothelial Growth Factor (VEGF) rescues retinal vasculatures and prevents disease progression in patients with neovascular Age‐Related Macular Degeneration (nAMD). However, systemic anti‐VEGF may increase the risk of thromboembolic related complications including stroke and TIA. This study aims to explore
A. H. Falemban, K. Söderberg‐Löfdal, F. Jonsson, S. Almlöf‐Sarman, M. von Euler, I. Westborg   +5 more
wiley   +1 more source

Evaluation of efficacy dexamethasone intravitreal implant compared to treatment with anti-VEGF in the treatment of diabetic macular edema

Senses and Sciences, 2014
Objective: The study compares the effectiveness of an intravitreal slow-release dexamethasone implant respect to an intravitreal injection of a anti-VEGF, ranibizumab, in the treatment of diabetic macular edema (DME).
Elena Pacella, Giuseppe La Torre, Paolo Turchetti, Concetta Merisola, Tommaso Lenzi, Francesco Mazzeo, Pietro Luchetti, Silvia Casale, Fernanda Pacella   +8 more
doaj   +1 more source

Efficacy and Safety of Various Treatments for Proliferative Diabetic Retinopathy: A Systematic Review and Network Meta-Analysis

Frontiers in Pharmacology, 2021
Diabetic retinopathy is the main cause of visual impairment and blindness. The proliferative diabetic retinopathy at the severe stage of diabetic retinopathy is more harmful to vision and even leads to total blindness.
Bo Zhang, Zhulin Zhou, Bingjie Zhang, Dan Wang   +3 more
doaj   +1 more source

1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy [PDF]

, 2015
published_or_final_versio
Gangwani, RA, Iu, LPL, Li, Q, Li, X, Ng, LK, Shi, X, Wong, YHI, Zhao, P   +7 more
core   +1 more source

Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial

JAMA ophthalmology, 2019
Importance To our knowledge, this is the first randomized clinical trial to compare visual outcomes and injection loads between ranibizumab and aflibercept using an identical treat-and-extend (TE) regimen for neovascular age-related macular degeneration (
M. Gillies, A. Hunyor, J. Arnold, R. Guymer, S. Wolf, P. Ng, F. Pecheur, I. McAllister   +7 more
semanticscholar   +1 more source

Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy [PDF]

Scientific Reports, 2019
AbstractThis retrospective study was to compare the efficacy of intravitreal injection of ranibizumab and aflibercept for patients with pachychoroid neovasculopathy. 54 eyes were initially treated with 3 monthly loading injections of ranibizumab or aflibercept. Treatment switching from ranibizumab to aflibercept, and aflibercept to photodynamic therapy
Byung Ju Jung, Joo Young Kim, Jae Hyung Lee, Jiwon Baek, Kook Lee, Won Ki Lee   +5 more
openaire   +3 more sources

Impact of anti‐VEGF therapy versus laser therapy on mortality and treatment outcomes in retinopathy of prematurity: A systematic review and meta‐analysis

Acta Ophthalmologica, EarlyView.
Abstract Purpose Retinopathy of prematurity (ROP) is a major cause of childhood blindness, and selecting the optimal treatment between anti‐vascular endothelial growth factor (anti‐VEGF) and laser therapy is crucial. Understanding their impact on key outcomes, particularly mortality, is essential for informed clinical decision‐making.
Wei‐De Wang, Ya‐Hsin Yao, Chiao‐Hsin Lan, Shih‐Heng Hung, Ta‐Hsin Tsung, Yann‐Guang Chen, Da‐Wen Lu, Jiann‐Torng Chen, Ke‐Hung Chien, Shu‐I Pao, Wei‐Ting Yen   +10 more
wiley   +1 more source

Secretory autophagy and epithelial‐to‐mesenchymal transition in cadaveric AMD samples: Novel pathways in disease progression

Acta Ophthalmologica, EarlyView.
Abstract Purpose To examine the presence of secretory autophagy and epithelial–mesenchymal transition (EMT) in the macular retinal pigment epithelium (RPE) of human cadaver eyes with different forms of age‐related macular degeneration (AMD). Methods Human cadaver macula samples representing dry and wet AMD, as well as age‐matched controls, were ...
Iswariyaraja Sridevi Gurubaran, Ali Koskela, Hanna Heloterä, Kai Kaarniranta   +3 more
wiley   +1 more source